Carbon monoxide-releasing molecule attenuates allograft airway rejection

Takashi Ohtsuka, Kaoru Kaseda, Takao Shigenobu, Tai Hato, Ikuo Kamiyama, Taichiro Goto, Mitsutomo Kohno, Masayuki Shimoda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Acute rejection after lung transplantation is the main risk factor for the development of bronchiolitis obliterans (BO). Carbon monoxide (CO) can provide anti-inflammatory effects and may serve to limit tissue injury in airway transplant. Here, we tested the ability of carbon monoxide releasing molecule-2 (CORM-2) to prevent airway rejection. Tracheal grafts from BALB/c or C57BL/6 were transplanted to C57BL/6 recipients. Experimental groups were treated with multiple doses of CORM-2. Histopathological evaluation of luminal obliteration was blindly reviewed. Immunohistochemistry and real-time RT-PCR analyses were performed. Allografts treated with CORM-2 revealed a striking reduction of thickening in epithelial and subepithelial airway layers (P < 0.01) at day 7 in orthotopic trachea transplantation model compared with allografts treated with vehicle. In heterotopic trachea transplantation model, CORM-2 treated allografts showed a reduction of luminal obliteration (P < 0.01) at days 14 and 21. There was also a concordant decrease in CD3+ lymphocytes and macrophages in CORM-2 treated allografts. IFN-γ, IL-2 and IL17A mRNA expressions were reduced dramatically by systemic administration of CORM-2. These data implicate CORM-2-derived CO has an important protective function in experimental BO, and may represent a target for the therapeutic intervention of chronic lung allograft rejection.

Original languageEnglish
Pages (from-to)741-747
Number of pages7
JournalTransplant International
Volume27
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Carbon Monoxide
Allografts
Bronchiolitis Obliterans
Trachea
Heterotopic Transplantation
Transplants
Lung Transplantation
Interleukin-2
Real-Time Polymerase Chain Reaction
Anti-Inflammatory Agents
Transplantation
Immunohistochemistry
Macrophages
Lymphocytes
Lung
Messenger RNA
Wounds and Injuries

Keywords

  • airway obstruction
  • carbon monoxide
  • lung transplantation

ASJC Scopus subject areas

  • Transplantation
  • Medicine(all)

Cite this

Carbon monoxide-releasing molecule attenuates allograft airway rejection. / Ohtsuka, Takashi; Kaseda, Kaoru; Shigenobu, Takao; Hato, Tai; Kamiyama, Ikuo; Goto, Taichiro; Kohno, Mitsutomo; Shimoda, Masayuki.

In: Transplant International, Vol. 27, No. 7, 2014, p. 741-747.

Research output: Contribution to journalArticle

Ohtsuka, T, Kaseda, K, Shigenobu, T, Hato, T, Kamiyama, I, Goto, T, Kohno, M & Shimoda, M 2014, 'Carbon monoxide-releasing molecule attenuates allograft airway rejection', Transplant International, vol. 27, no. 7, pp. 741-747. https://doi.org/10.1111/tri.12314
Ohtsuka, Takashi ; Kaseda, Kaoru ; Shigenobu, Takao ; Hato, Tai ; Kamiyama, Ikuo ; Goto, Taichiro ; Kohno, Mitsutomo ; Shimoda, Masayuki. / Carbon monoxide-releasing molecule attenuates allograft airway rejection. In: Transplant International. 2014 ; Vol. 27, No. 7. pp. 741-747.
@article{c8a2152216914b8f922c3b24fc3afe8b,
title = "Carbon monoxide-releasing molecule attenuates allograft airway rejection",
abstract = "Acute rejection after lung transplantation is the main risk factor for the development of bronchiolitis obliterans (BO). Carbon monoxide (CO) can provide anti-inflammatory effects and may serve to limit tissue injury in airway transplant. Here, we tested the ability of carbon monoxide releasing molecule-2 (CORM-2) to prevent airway rejection. Tracheal grafts from BALB/c or C57BL/6 were transplanted to C57BL/6 recipients. Experimental groups were treated with multiple doses of CORM-2. Histopathological evaluation of luminal obliteration was blindly reviewed. Immunohistochemistry and real-time RT-PCR analyses were performed. Allografts treated with CORM-2 revealed a striking reduction of thickening in epithelial and subepithelial airway layers (P < 0.01) at day 7 in orthotopic trachea transplantation model compared with allografts treated with vehicle. In heterotopic trachea transplantation model, CORM-2 treated allografts showed a reduction of luminal obliteration (P < 0.01) at days 14 and 21. There was also a concordant decrease in CD3+ lymphocytes and macrophages in CORM-2 treated allografts. IFN-γ, IL-2 and IL17A mRNA expressions were reduced dramatically by systemic administration of CORM-2. These data implicate CORM-2-derived CO has an important protective function in experimental BO, and may represent a target for the therapeutic intervention of chronic lung allograft rejection.",
keywords = "airway obstruction, carbon monoxide, lung transplantation",
author = "Takashi Ohtsuka and Kaoru Kaseda and Takao Shigenobu and Tai Hato and Ikuo Kamiyama and Taichiro Goto and Mitsutomo Kohno and Masayuki Shimoda",
year = "2014",
doi = "10.1111/tri.12314",
language = "English",
volume = "27",
pages = "741--747",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Carbon monoxide-releasing molecule attenuates allograft airway rejection

AU - Ohtsuka, Takashi

AU - Kaseda, Kaoru

AU - Shigenobu, Takao

AU - Hato, Tai

AU - Kamiyama, Ikuo

AU - Goto, Taichiro

AU - Kohno, Mitsutomo

AU - Shimoda, Masayuki

PY - 2014

Y1 - 2014

N2 - Acute rejection after lung transplantation is the main risk factor for the development of bronchiolitis obliterans (BO). Carbon monoxide (CO) can provide anti-inflammatory effects and may serve to limit tissue injury in airway transplant. Here, we tested the ability of carbon monoxide releasing molecule-2 (CORM-2) to prevent airway rejection. Tracheal grafts from BALB/c or C57BL/6 were transplanted to C57BL/6 recipients. Experimental groups were treated with multiple doses of CORM-2. Histopathological evaluation of luminal obliteration was blindly reviewed. Immunohistochemistry and real-time RT-PCR analyses were performed. Allografts treated with CORM-2 revealed a striking reduction of thickening in epithelial and subepithelial airway layers (P < 0.01) at day 7 in orthotopic trachea transplantation model compared with allografts treated with vehicle. In heterotopic trachea transplantation model, CORM-2 treated allografts showed a reduction of luminal obliteration (P < 0.01) at days 14 and 21. There was also a concordant decrease in CD3+ lymphocytes and macrophages in CORM-2 treated allografts. IFN-γ, IL-2 and IL17A mRNA expressions were reduced dramatically by systemic administration of CORM-2. These data implicate CORM-2-derived CO has an important protective function in experimental BO, and may represent a target for the therapeutic intervention of chronic lung allograft rejection.

AB - Acute rejection after lung transplantation is the main risk factor for the development of bronchiolitis obliterans (BO). Carbon monoxide (CO) can provide anti-inflammatory effects and may serve to limit tissue injury in airway transplant. Here, we tested the ability of carbon monoxide releasing molecule-2 (CORM-2) to prevent airway rejection. Tracheal grafts from BALB/c or C57BL/6 were transplanted to C57BL/6 recipients. Experimental groups were treated with multiple doses of CORM-2. Histopathological evaluation of luminal obliteration was blindly reviewed. Immunohistochemistry and real-time RT-PCR analyses were performed. Allografts treated with CORM-2 revealed a striking reduction of thickening in epithelial and subepithelial airway layers (P < 0.01) at day 7 in orthotopic trachea transplantation model compared with allografts treated with vehicle. In heterotopic trachea transplantation model, CORM-2 treated allografts showed a reduction of luminal obliteration (P < 0.01) at days 14 and 21. There was also a concordant decrease in CD3+ lymphocytes and macrophages in CORM-2 treated allografts. IFN-γ, IL-2 and IL17A mRNA expressions were reduced dramatically by systemic administration of CORM-2. These data implicate CORM-2-derived CO has an important protective function in experimental BO, and may represent a target for the therapeutic intervention of chronic lung allograft rejection.

KW - airway obstruction

KW - carbon monoxide

KW - lung transplantation

UR - http://www.scopus.com/inward/record.url?scp=84902550776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902550776&partnerID=8YFLogxK

U2 - 10.1111/tri.12314

DO - 10.1111/tri.12314

M3 - Article

C2 - 24628975

AN - SCOPUS:84902550776

VL - 27

SP - 741

EP - 747

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 7

ER -